vimarsana.com

Page 47 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் பரிமாற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alamos Gold Acquires Trillium Mining Consolidating Large Land Package Adjacent to Island Gold Mine

Alamos Gold Acquires Trillium Mining Consolidating Large Land Package Adjacent to Island Gold Mine TORONTO, Dec. 17, 2020 Alamos Gold Inc. ( TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) is pleased to announce that it has completed an agreement to acquire Trillium Mining Corp. (“Trillium”) for cash consideration of C$25 million. Trillium holds a large land package comprised of 5,418 hectares (“ha”) directly adjacent to, and along strike from the Island Gold Deposit within the Michipicoten Greenstone Belt. The acquisition has significantly expanded the Company’s land package around the Island Gold mine to 14,929 ha, a 57% increase (see Figures 1 and 2). This newly acquired land includes significant exploration potential in proximity to existing high-grade Mineral Resources and regionally.

【大選更新12 20】川普:戒嚴令是假新聞 | 美國大選 | 大選舞弊

【大選更新12 20】川普:戒嚴令是假新聞 | 美國大選 | 大選舞弊
epochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from epochtimes.com Daily Mail and Mail on Sunday newspapers.

Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Share: Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world Mereo receives $50 million upfront and is eligible for milestones up to $254 million NOVATO, Calif., LONDON, and REDWOOD CITY, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ:MREO, AIM: MPH)), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human mono

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.